^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KDR elevation

    i
    Other names: KDR, CD309, FLK1, VEGFR, VEGFR2, Kinase insert domain receptor (a type III receptor tyrosine kinase)
    Entrez ID:
    3791
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    almost2years
    Gene expression-based prediction of pazopanib efficacy in sarcoma. (PubMed, Eur J Cancer)
    A score based on the combined expression of NTRK3, IGF1R and KDR allows the identification of patients with sarcoma and with good, intermediate and poor outcome following pazopanib therapy and warrants prospective investigation as a predictive tool to optimise the use of this drug in the clinic.
    Journal
    |
    NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • KDR (Kinase insert domain receptor)
    |
    KDR elevation • NTRK expression
    |
    Votrient (pazopanib)
    almost2years
    Characterization of the Expression of Angiogenic Factors in Cutaneous Squamous Cell Carcinoma of Domestic Cats. (PubMed, Vet Sci)
    Immunolocalization in tissue showed increased expression of all measured factors and receptors in tumor cells compared to NHS and surrounding vasculature. We conclude that the factors measured may play a pivotal role in CSCC growth, although further studies are needed to clarify the role of angiogenic factors in feline CSCC.
    Journal
    |
    KDR (Kinase insert domain receptor) • FLT1 (Fms-related tyrosine kinase 1)
    |
    KDR elevation • VEGFA expression
    2years
    Three-dimensional tumor angiogenesis mapping in metastatic gastric cancer patients (AACR 2022)
    Understanding angiogenesis inhibition as part of a therapeutic strategy considering tumor microenvironment has important clinical implications. It would be a significant outcome for our analysis system to bring therapeutic benefits to GC patients.
    Clinical
    |
    KDR (Kinase insert domain receptor)
    |
    KDR expression • KDR elevation
    |
    Cyramza (ramucirumab)